Eric M. Dube
CIK: 0001763494
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Travere Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (47 total)
- Oct 15, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct128.1K shares at avg. $52.97$6.8M - Oct 15, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct200K shares at avg. $8.93$1.8M - Oct 15, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct43.7K shares at avg. $26.88$1.2M - Oct 15, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct37.3K shares at avg. $54.20$2.0M - Oct 15, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct78.4K shares at avg. $55.02$4.3M - Sep 17, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct101.7K shares at avg. $64.59$6.6M - Sep 17, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct6.8K shares at avg. $64.95$442K - Sep 17, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct108.5K shares at avg. $23.34$2.5M - Sep 16, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct195.8K shares at avg. $23.34$4.6M - Sep 16, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct96.1K shares at avg. $63.64$6.1M - Sep 16, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct99.7K shares at avg. $63.26$6.3M - Sep 15, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct63.5K shares at avg. $61.99$3.9M - Sep 15, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct95.7K shares at avg. $23.34$2.2M - Sep 15, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct270 shares at avg. $65.31$18K - Sep 15, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct3.1K shares at avg. $63.64$197K - Sep 15, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct28.8K shares at avg. $62.66$1.8M - May 6, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct22.5K shares at avg. $43.95$989K - May 4, 2026TVTX
Travere Therapeutics, Inc.
Award(A)DirectPerformance-based restricted stock units
45K shares- - May 4, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct22.5K shares- - Apr 15, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct20 shares at avg. $42.66$853.2 - Apr 15, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct56.8K shares at avg. $41.01$2.3M - Apr 15, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct7.2K shares at avg. $41.75$299K - Apr 13, 2026TVTX
Travere Therapeutics, Inc.
Award(A)Direct64K shares- - Apr 1, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct25.1K shares at avg. $31.46$790K - Apr 1, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct60K shares at avg. $15.46$928K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 15, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 128,065 | $52.97 | $6,783,244 | Direct |
| Oct 15, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 200,000 | $8.93 | $1,786,000 | Direct |
| Oct 15, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 43,735 | $26.88 | $1,175,597 | Direct |
| Oct 15, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 37,270 | $54.20 | $2,020,023 | Direct |
| Oct 15, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 78,400 | $55.02 | $4,313,403 | Direct |
| Sep 17, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 101,691 | $64.59 | $6,567,876 | Direct |
| Sep 17, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 6,802 | $64.95 | $441,795 | Direct |
| Sep 17, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 108,493 | $23.34 | $2,532,227 | Direct |
| Sep 16, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 195,841 | $23.34 | $4,570,929 | Direct |
| Sep 16, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 96,125 | $63.64 | $6,117,289 | Direct |
| Sep 16, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 99,716 | $63.26 | $6,307,964 | Direct |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 63,498 | $61.99 | $3,936,527 | Direct |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 95,666 | $23.34 | $2,232,844 | Direct |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 270 | $65.31 | $17,634 | Direct |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 3,102 | $63.64 | $197,422 | Direct |
| Sep 15, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 28,796 | $62.66 | $1,804,222 | Direct |
| May 6, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 22,500 | $43.95 | $988,875 | Direct |
| May 4, 2026 | TVTX Travere Therapeutics, Inc. | Award(A) Performance-based restricted stock units | 45,000 | - | - | Direct |
| May 4, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 22,500 | - | $0 | Direct |
| Apr 15, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 20 | $42.66 | $853 | Direct |
| Apr 15, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 56,815 | $41.01 | $2,329,983 | Direct |
| Apr 15, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 7,165 | $41.75 | $299,139 | Direct |
| Apr 13, 2026 | TVTX Travere Therapeutics, Inc. | Award(A) | 64,000 | - | $0 | Direct |
| Apr 1, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 25,098 | $31.46 | $789,583 | Direct |
| Apr 1, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 60,000 | $15.46 | $927,600 | Direct |
1-25 of 47 transactions
About Dube Eric M
Dube Eric M (SEC CIK 0001763494) files insider reports with the SEC as CHIEF EXECUTIVE OFFICER of Travere Therapeutics, Inc. (TVTX).
Signal8 holds 14 ownership filings by Dube Eric M, all Form 4s, filed between Sep 9, 2024 and Oct 19, 2026. Those filings report 47 transactions, from Sep 5, 2024 to Oct 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Dube Eric M's filings is in SAN DIEGO, CA.
Recent filings by Dube Eric M
- Oct 15, 2026: Open-market sale of TVTX shares (Form 4, code S).
- Oct 15, 2026: Option exercises of TVTX shares (2 lines, Form 4, code M).
- Oct 15, 2026: Open-market sales of TVTX shares (2 lines, Form 4, code S).
- Sep 17, 2026: Open-market sales of TVTX shares (2 lines, Form 4, code S).
- Sep 17, 2026: Option exercise of TVTX shares (Form 4, code M).
Other insiders filing for Travere Therapeutics, Inc. (TVTX)
- ROTE WILLIAM E., Chief Research Officer
- Heerma Peter, EVP, CHIEF COMMERCIAL OFFICER
- Inrig Jula, EVP, Head of R&D & CMO
- REED ELIZABETH E, Chief Legal Officer and GC
- Cline Christopher R., CHIEF FINANCIAL OFFICER
- Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER